Skip to content
10-Q

Quarterly Report

Akoya Biosciences, Inc.

0001558370-24-010883

← back to feed
Filed
Aug 6, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jul 31, 2024 49.5M sh
Shares Diluted Q2 2024 · Jun 30, 2024 49.42M sh
Shares Diluted Q2 2024 · Jun 30, 2024 49.3M sh
Shares Diluted Q2 2024 · Jun 30, 2023 40.64M sh
Shares Diluted Q2 2024 · Jun 30, 2023 39.49M sh
Capex Q2 2024 · Jun 30, 2024 $980K
Capex Q2 2024 · Jun 30, 2023 $2.23M
Operating Cash Flow Q2 2024 · Jun 30, 2024 −$31.87M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$31.56M
Long Term Debt Q2 2024 · Jun 30, 2024 $75.68M
Long Term Debt Q2 2024 · Dec 31, 2023 $75.25M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $8.92M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $83.13M
Stockholders Equity Q2 2024 · Jun 30, 2024 $22.25M
Stockholders Equity Q2 2024 · Mar 31, 2024 $32.72M
Stockholders Equity Q2 2024 · Dec 31, 2023 $53.77M
Stockholders Equity Q2 2024 · Jun 30, 2023 $71.9M
Stockholders Equity Q2 2024 · Mar 31, 2023 $42.12M
Stockholders Equity Q2 2024 · Dec 31, 2022 $58.58M
Current Liabilities Q2 2024 · Jun 30, 2024 $32.74M
Current Liabilities Q2 2024 · Dec 31, 2023 $35.35M
Total Liabilities Q2 2024 · Jun 30, 2024 $121.5M
Total Liabilities Q2 2024 · Dec 31, 2023 $126.6M
Current Assets Q2 2024 · Jun 30, 2024 $89.51M
Current Assets Q2 2024 · Dec 31, 2023 $121.79M
Total Assets Q2 2024 · Jun 30, 2024 $143.75M
Total Assets Q2 2024 · Dec 31, 2023 $180.37M
Eps Diluted Q2 2024 · Jun 30, 2024 −$0.27
Eps Diluted Q2 2024 · Jun 30, 2024 −$0.74
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.51
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.00
Eps Basic Q2 2024 · Jun 30, 2024 −$0.27
Eps Basic Q2 2024 · Jun 30, 2024 −$0.74
Eps Basic Q2 2024 · Jun 30, 2023 −$0.51
Eps Basic Q2 2024 · Jun 30, 2023 −$1.00
Sga Expense Q2 2024 · Jun 30, 2024 $19.09M
Sga Expense Q2 2024 · Jun 30, 2024 $38.96M
Sga Expense restated Q2 2024 · Jun 30, 2023 $23.91M
Sga Expense restated Q2 2024 · Jun 30, 2023 $47.03M
Rd Expense Q2 2024 · Jun 30, 2024 $5.29M
Rd Expense Q2 2024 · Jun 30, 2024 $10.84M
Rd Expense restated Q2 2024 · Jun 30, 2023 $6.92M
Rd Expense restated Q2 2024 · Jun 30, 2023 $13.3M
Net Income Q2 2024 · Jun 30, 2024 −$13.15M
Net Income Q2 2024 · Jun 30, 2024 −$36.63M
Net Income Q2 2024 · Mar 31, 2024 −$23.48M
Net Income Q2 2024 · Jun 30, 2023 −$20.8M
Net Income Q2 2024 · Jun 30, 2023 −$39.61M
Net Income Q2 2024 · Mar 31, 2023 −$18.8M
Operating Income Q2 2024 · Jun 30, 2024 −$11.08M
Operating Income Q2 2024 · Jun 30, 2024 −$32.67M
Operating Income Q2 2024 · Jun 30, 2023 −$19.24M
Operating Income Q2 2024 · Jun 30, 2023 −$36.68M
Gross Profit Q2 2024 · Jun 30, 2024 $13.39M
Gross Profit Q2 2024 · Jun 30, 2024 $21.77M
Gross Profit Q2 2024 · Jun 30, 2023 $12.12M
Gross Profit Q2 2024 · Jun 30, 2023 $24.41M
Cost Of Revenue Q2 2024 · Jun 30, 2024 $9.78M
Cost Of Revenue Q2 2024 · Jun 30, 2024 $19.75M
Cost Of Revenue Q2 2024 · Jun 30, 2023 $11.41M
Cost Of Revenue Q2 2024 · Jun 30, 2023 $20.52M
Revenue Q2 2024 · Jun 30, 2024 $23.16M
Revenue Q2 2024 · Jun 30, 2024 $41.51M
Revenue Q2 2024 · Jun 30, 2023 $23.52M
Revenue Q2 2024 · Jun 30, 2023 $44.93M